Tronox Ltd (TROX) Drops 6.24% on January 01

Equities Staff |

Tronox Ltd (TROX) was one of the Russell 2000's biggest losers for Friday January 01 as the stock slid 6.24% to $3.91, a loss of $-0.26 per share. Starting at an opening price of $4.14 a share, the stock traded between $3.87 and $4.33 over the course of the trading day. Volume was 878,194 shares over 3,209 trades, against an average daily volume of 1.4 million shares and a total float of 115.67 million.

The losses send Tronox Ltd down to a market cap of $452.28 million. In the last year, Tronox Ltd has traded between $24.20 and $2.98, and its 50-day SMA is currently $5.10 and 200-day SMA is $10.80.

Tronox Ltd is engaged in producing and marketing of titanium bearing mineral sands and titanium dioxide pigment. The Company operates under two segments, which are Mineral Sands and Pigment.

Tronox Ltd is based out of Stamford, CT and has some 3,400 employees. Its CEO is Thomas Casey.

For a complete fundamental analysis analysis of Tronox Ltd, check out Equities.com’s Stock Valuation Analysis report for TROX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

Airbnb

Airbnb is a community marketplace for people to list, discover, and book unique accommodations around the world — online or from a mobile phone. Whether an apartment for a night,…